Dr. Unegbu explains that the study has three main objectives: to discover the nature and scale of the problem of pediatric pulmonary hypertension, to investigate the pharmacological therapies available, and to study the efficacy and safety of PDE-5 inhibitors.
The study concluded that the benefits of PDE-5 inhibitors in the treatment of pediatric pulmonary hypertension outweighed the downfalls.
Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.